Some cerebrospinal fluid (CSF) Alzheimer’s disease (AD) biomarker profiles are difficult to interpret. We investigated one such case: normal Aβ42 and pathologically increased levels of Tau and P-Tau (Tau&PTau profile). We first extracted details of 184 patients with a Tau&PTau profile who had been followed up in Strasbourg, France (cohort 1) and whose diagnosis has been reviewed. Secondly, we recovered and analyzed the AD biomarker results and clinical diagnoses of a cohort of 1199 patients also followed up in Strasbourg (cohort 2). In cohort 1, 57% of patients were patients with comorbidity: they had both Alzheimer’s disease and dementia with Lewy bodies (DLB) (AD+DLB). In cohort 2, among patients with a Tau&PTau profile: between 39.6 and 53.1% had comorbidity with AD, with more than half of the comorbidities being DLB. In cohort 2, among patients with AD+DLB, the majority (64.4%) had a Tau&PTau profile. These results show that patients with AD+DLB comorbidity mainly have a Tau&PTau profile. These results are relatively counterintuitive, given that AD and DLB are two diseases in which it is common, even systematic, to find a CSF Aβ42 decrease. However, the combination of the two diseases, or more broadly, AD comorbidity, indicates higher levels of Aβ42 than in pure AD. Graphical Abstract
Le 31 janvier 2001, la première Yaris sortait de l’usine Toyota de Valenciennes. Vingt-cinq ans plus tard, l’usine du constructeur automobile japonais est la plus importante de France, et peut-être la plus performante d’Europe. Retour sur un succès, et sur ses leçons.
La réforme du métier d'infirmière, qui offre aux professionnelles un rôle élargi et beaucoup plus central dans le système de soins, va entrer en vigueur. Une petite révolution pour les intéressées.
